| Sep 18 |
Merck’s Keytruda label expanded in the U.S. for mesothelioma
|
| Sep 18 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
|
| Sep 18 |
Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trial
|
| Sep 17 |
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
|
| Sep 17 |
ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial
|
| Sep 17 |
Merck, Daiichi post late-stage trial win for novel lung cancer therapy
|
| Sep 17 |
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
|
| Sep 16 |
BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC
|
| Sep 16 |
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
|
| Sep 15 |
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
|
